PUBLIC COMPANY
save$ALNYALNYLAM PHARMACEUTICALS, INC.
$ALNY229.30-5.49%Cambridge, MA, USupdated 7h ago
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
community read0 votes
pipeline
6
marketed
4
phase 3
2
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Phase 34Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
- phase3TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- phase2A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- phase1A Study to Evaluate ALN-6222 in Participants With Obesity
- phase2HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
- phase2A Study to Evaluate ALN-2232 in Participants With Obesity
- phase1A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
- —Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 6, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$300K↗
- Apr 6, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$274K↗
- Apr 6, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$97K↗
- Apr 6, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$66K↗
- Apr 6, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$18K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$114K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$84K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$79K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$72K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$67K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$47K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$27K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$26K↗
- Apr 2, 26SELLMcLaughlin Melissa· Chief Human Resources Officer−$3K↗
- Mar 5, 26SELLGarg Pushkal· EVP Chief R&D−$239K↗
- Mar 5, 26SELLGarg Pushkal· EVP Chief R&D−$211K↗
- Mar 5, 26SELLGarg Pushkal· EVP Chief R&D−$166K↗
- Mar 5, 26SELLGarg Pushkal· EVP Chief R&D−$163K↗
- Mar 5, 26SELLFitzgerald Kevin Joseph· CSO & EVP, Head of Research−$75K↗
- Mar 5, 26SELLFitzgerald Kevin Joseph· CSO & EVP, Head of Research−$50K↗
🐶 Hiring Signal
next earnings Oct 29, 2026
News
- After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.fiercebiotech · 9d ago
- Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchiseAlnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.biospace · 20d ago
- AstraZeneca, Ionis drug fails big heart disease study in major setbackEplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.biopharma_dive · 1mo ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 3mo ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that